Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
Developing “super soldiers” of particular white blood cells to promote an anti-tumor reaction has been demonstrated in a series of well-designed experiments.
Researchers at Case Western Reserve University, using artificial intelligence (AI) to analyze simple tissue scans, say they have discovered biomarkers that could tell doctors which lung cancer patients might actually get worse from immunotherapy.
For patients with cancers that do not respond to immunotherapy drugs, adjusting the composition of microorganisms in the intestines--known as the gut microbiome--through the use of a stool, or fecal, transplants may help some of these individuals respond to the immunotherapy drugs, a new study suggests.
New research and analysis appearing in the Journal of the Academy of Nutrition and Dietetics, published by Elsevier, highlights the barriers cancer survivors face in maintaining a healthy diet, as well as the role nutrition may play in cancer risk and treatment.
Cancer cells are smart when it comes to anti-cancer drugs, evolving and becoming resistant to even the strongest chemotherapies over time.
New research from CU Cancer Center member Jing Hong Wang, MD, PhD, and recent University of Colorado Immunology program graduate Rachel Woolaver, PhD, may help researchers develop more effective personalized immunotherapy for cancer patients.
The abundant presence of an enzyme known as low molecular weight protein tyrosine phosphatase (LMWPTP) in tumor cells has long been considered an indicator of cancer aggressiveness and metastatic potential.
CAR T cells are a breakthrough class of effective but often toxic cancer therapies. To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug.
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination - of irinotecan, cetuximab, and vemurafenib - is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab.
Cancer is one of the world's greatest health afflictions because, unlike some diseases, it is a moving target, constantly evolving to evade and resist treatment.
The research group led by Dr Sjoerd van Wijk from the Institute of Experimental Cancer Research in Paediatrics at Goethe University already two years ago found evidence indicating that the anti-diarrhea drug loperamide could be used to induce cell death in glioblastoma cell lines.
Chemotherapy not only attacks cancer cells but also targets all cells in the human body. This is the reason why patients receiving this treatment generally experience adverse side effects, like hair loss, physical weakness, and nausea.
Scientists from the University of California, Los Angeles have discovered a promising diagnostic marker that may help predict the response of cervical cancer patients to standard radiation and chemotherapy treatments.
One of the hallmarks of Glioblastoma (GBM), the most aggressive type of brain cancer, is its high invasive capacity, which leads to its expansion into the normal brain tissue.
Researchers at Tel Aviv University have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers.
A key way radiation therapy and chemotherapy work is by making highly lethal double-strand breaks in the DNA of cancer cells.
Researchers say they've identified a way to disrupt a process that promotes the growth of pancreatic cancers -- one of the most difficult and deadly cancers to treat.
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.
Scientists have developed a novel process that may help personalize anticancer treatments.
In recent years, the microbiota -- the community of bacteria and other microorganisms that live on and in the human body -- has captured the attention of scientists and the public, in part because it's become easier to study. It has been linked to many aspects of human health.